Genmab — Juli 2023
-
Genmab Announces Net Sales of
DARZALEX
(daratumumab) for Second Quarter of 2023 https://www.proinvestor.com/investornyt/1018084/genmab-announces-net-sales-of-darzalex-daratumumab-for-second-quarter-of-2023 -
Johnson & Johnson opjusterer - Darzalex-salg stort set som ventet https://www.proinvestor.com/investornyt/1018102/johnson-johnson-opjusterer-darzalex-salg-stort-set-som-ventet
-
-
Yderligere beføjelser? Det er et bestyrelsesmedlem og ikke et direktionsmedlem. Håber du kender forskellen i den opbygning der ligger mellem direktion og bestyrelse.
-
High-Growth Biopharma: Thriving Through Change & Volatility
To navigate growth, biopharma companies must empower leaders, maintain an agile culture that prioritizes the patient, and invest in R&D.
(www.russellreynolds.com)
-
-
J&J forventer at behandle 3/4 af alle MM pts inden udgangen af dette tiår. De føler sig bedre rustet til IRA end andre firmaer (hexa-cd38?). De nævnte også noget om at de altid var på jagt efter muligheder der kunne skabe mere værdi for et asset i deres hånd, end de havde pt.
-
J&J again boosts full-year outlook as Darzalex https://firstwordpharma.com/story/5762723
-
J&J's Darzalex stays on its upward trajectory as company adds $1B to annual sales projection https://www.fiercepharma.com/pharma/johnson-johnsons-darzalex-continues-its-upward-trajectory-company-boosts-2023-revenue
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind